Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

New Trials

28 Apr 2008 08:09

Plant Health Care PLC28 April 2008 For immediate release 28 APRIL 2008 PLANT HEATH CARE PLC ("Plant Heath Care" or "the Company") Plant Health Care, Inc. initiates large scale grower tests for a ProActTM + Glyphosate product Plant Heath Care, (AIM: PHC.L), a leading provider of natural products forplants and soil, has initiated a large scale field trial program for corn,soybeans, and cotton to further evaluate the already established benefits ofusing ProActTM in combination with glyphosate, the world's most commonly usedherbicide, when applied over-the-top of glyphosate resistant crops. Five yearsof independent testing have demonstrated significant yield increases in cottonand corn when treated with a combination of ProAct and glyphosate. ProAct is afoliar spray product for reducing nematode populations and improving overallplant health. ProAct, which is the only foliar spray product labeled for useagainst nematodes in corn and soybeans, contains Harpin, a second generationharpin protein formulated as a wettable dry granule. PHC Director of Field Biology Ned French says, "ProAct increases yields. Thecomprehensive data from multi-year ProAct research shows average increases of2.5 bushels/acre in soybeans, 7 bushels/acre in corn, and 68 pounds of cottonlint/acre. These yield increases translate into economic returns of $28, $35,and $50/acre, respectively. The ProAct + Glyphosate Program will help bothgroups learn more about the benefits in real-world farming conditions." All participants will be asked to join a series of post-harvest teleconferencesto discuss how the ProAct + glyphosate tank-mix performed on their farms. PHCwill use the information gleaned from the teleconferences as the basis forbetter understanding farmer needs and perceptions as they relate to the use ofProAct + glyphosate. PHC, started in 1995, was originally focused on horticulture, turf, vegetablesand high value crops. The company started targeting field crops -corn, soybeans,and cotton - in 2007 based on its acquisition of harpin protein technologyproducts such as ProAct. ProAct contains the most recently developed andeffective generation of harpin proteins. Plant Health Care, Inc., headquartered in Pittsburgh, PA, is a wholly ownedsubsidiary of Plant Health Care plc (AIM:PHC), a leading provider of naturalproducts for plants and soil. PHC has operations in the United States, Mexico,the United Kingdom, Spain, and the Netherlands. PHC products are used in theagriculture, landscape, horticulture and land reclamation industries and areenvironmentally beneficial. Through the commercialization of these products, PHCis capitalizing on current long-term trends toward natural systems andbiological products for plant care and soil and water management. For moreinformation and complete details pertaining to the ProAct SatisfactionGuarantee, go to www.planthealthcare.com. -ends- For further information: Plant Heath Care plc John Brady, Chief Executive Tel: 001 603 525 3702 Evolution Securities Limited Tim Worlledge/ Tim Redfern Tel: 020 7071 4300 Tavistock Communications Jeremy Carey/Matt Ridsdale Tel: 020 7920 3150 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
12th Nov 20193:56 pmRNSHolding(s) in Company
6th Nov 201912:57 pmRNSInvestment in Company by Ospraie Ag Science LLC
30th Oct 20197:00 amRNSAppointment of new Board Directors
3rd Oct 20192:50 pmRNSDirector/PDMR Shareholding
30th Sep 20197:00 amRNSInterim Report ended 30 June 2019
9th Sep 20197:00 amRNSPilot production of PREtec peptides
19th Aug 20197:00 amRNSBlock listing Interim Review
15th Aug 20197:00 amRNSProgress with PREtec field trials in Brazil
5th Aug 20195:18 pmRNSHolding(s) in Company
25th Jun 20197:00 amRNSNew Distribution Agreement with Wilbur-Ellis
12th Jun 201911:05 amRNSResult of AGM
30th Apr 20194:19 pmRNSAnnual Report & Accounts and AGM Notice Published
10th Apr 20197:00 amRNSResults for the year ended 31 December 2018
27th Mar 20193:41 pmRNSHolding(s) in Company
28th Feb 20197:00 amRNSNew Technology Update
19th Feb 20197:00 amRNSBlock listing Interim Review
29th Jan 20197:00 amRNSTrading Statement
24th Jan 20195:58 pmRNSHolding(s) in Company
21st Dec 20187:00 amRNSTrading Statement
28th Nov 20187:00 amRNSNew Technology Update
21st Nov 20187:00 amRNSPlant Health Care ProAct® Wins Top Industry Award
19th Nov 20187:00 amRNSPlant Health Care to present at Mello London
14th Nov 20187:00 amRNSPositive Developments with Harpin
8th Nov 20187:00 amRNSChange of Adviser
5th Nov 20187:00 amRNSHolding(s) in Company
18th Sep 20187:00 amRNSInterim Report ended 30 June 2018
12th Sep 20187:00 amRNSUS Announces Harpin aß Product Launch in Corn
20th Aug 20187:00 amRNSBlock listing Interim Review
30th Jul 20187:00 amRNSUpdate on sugarcane in Brazil
16th Jul 20187:00 amRNSTrading Statement
6th Jun 20182:39 pmRNSHolding(s) in Company
6th Jun 201811:14 amRNSResult of AGM
30th May 20187:00 amRNSGrant of Options
4th May 20185:59 pmRNSHolding(s) in Company
30th Apr 20183:11 pmRNSPublication of Annual Report and Notice of AGM
10th Apr 20187:00 amRNSResults for the year ended 31 December 2017
8th Mar 20187:00 amRNSBlock listing Interim Review
7th Mar 20183:07 pmRNSHolding(s) in Company
7th Mar 20183:06 pmRNSHolding(s) in Company
7th Mar 20183:02 pmRNSHolding(s) in Company
2nd Mar 20185:48 pmRNSHolding(s) in Company
27th Feb 20184:12 pmRNSResult of Placing and Subscription
27th Feb 20187:00 amRNSProposed Placing and Subscription
24th Jan 20187:00 amRNSTrading Statement
12th Dec 20177:00 amRNSNew Technology Update
8th Dec 20174:35 pmRNSPrice Monitoring Extension
6th Dec 20174:40 pmRNSSecond Price Monitoring Extn
6th Dec 20174:35 pmRNSPrice Monitoring Extension
18th Sep 20177:00 amRNSHalf-year Report
21st Aug 20177:00 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.